Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy

被引:52
作者
Ali, Sahra [1 ]
Jones, Gail L. [2 ]
Culligan, Dominic J. [3 ]
Marsden, Philippa J. [4 ]
Russell, Nigel [5 ]
Embleton, Nicholas D. [6 ]
Craddock, Charles [7 ]
机构
[1] Hull & East Yorkshire Hosp NHS Trust, Hull Royal Infirm, Dept Haematol, Kingston Upon Hull, N Humberside, England
[2] Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Dept Haematol, Newcastle Upon Tyne, Tyne & Wear, England
[3] Aberdeen Royal Infirm, Dept Haematol, Aberdeen, Scotland
[4] Newcastle Upon Tyne Hosp NHS Fdn Trust, Royal Victoria Infirm, Dept Womens Serv, Newcastle Upon Tyne, Tyne & Wear, England
[5] Nottingham Univ Hosp NHS Trust, City Hosp Nottingham, Dept Haematol, Nottingham, England
[6] Newcastle Upon Tyne Hosp NHS Fdn Trust, Royal Victoria Infirm, Dept Paediat, Newcastle Upon Tyne, Tyne & Wear, England
[7] Univ Birmingham, Dept Haematol, Birmingham, W Midlands, England
关键词
acute myeloid leukaemia; pregnancy; chemotherapy; foetus; teratogenic risk; TERM FOLLOW-UP; THERAPY; EXPERIENCE; CANCER;
D O I
10.1111/bjh.13554
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pregnant women should be managed by a multidisciplinary team that includes haematologists, obstetricians, neonatologists and anaesthetists (Grade 1C) As for non-pregnant patients, acute myeloid leukaemia (AML) should be diagnosed using the World Health Organization (WHO) classification (Grade 1A) Women diagnosed with AML in pregnancy should be treated without delay (Grade 1B) When the diagnosis of AML is made in the first trimester, a successful pregnancy outcome is unlikely and spontaneous pregnancy loss in this situation carries considerable risks for the mother. The reasons for and against elective termination should be discussed with the patient (Grade 2C) In the case of presentation beyond 32weeks gestation, it may be reasonable to deliver the foetus prior to commencement of chemotherapy (Grade 2C) Between 24 and 32weeks, risks of foetal chemotherapy exposure must be balanced against risks of prematurity following elective delivery at that stage of gestation (Grade 1C) The risk-benefit ratio must be carefully considered before using any drugs in pregnancy (Grade 1C) Where AML induction chemotherapy is delivered, a standard daunorubicin, cytarabine 3+10 schedule should be used (Grade 1B) Chemotherapy should be dosed according to actual body weight and adjustments made for weight changes during treatment (Grade 1C) Quinolones, tetracyclines and sulphonamide use should be avoided in pregnancy (Grade 1B) Amphotericin B or lipid derivatives are the antifungal of choice in pregnancy (Grade 2C) Cytomegalovirus (CMV)-negative blood products should be administered during pregnancy regardless of CMV serostatus (Grade 1B) A course of corticosteroids should be considered if delivery is anticipated between 24 and 35weeks gestation, given over a 48-h period during the week prior to delivery (Grade 1A) Use of magnesium sulphate should be considered in the 24h prior to delivery if this is before 30weeks gestation (Grade 1A) Where possible, delivery should be planned for a time when the woman is at least 3weeks post-chemotherapy to minimize risk of neonatal myelosuppression (Grade 1C) Planned delivery is easier to manage than spontaneous labour; induction of labour is usually advised (Grade 2C) Epidural analgesia should be avoided in a woman who is significantly thrombocytopenic (platelet count <80x10(9)/l) and/or neutropenic (white blood cell count <1x10(9)/l): (Grade 1C) Elective caesarean section should only be recommended for obstetric indications (Grade 2C) Antibiotics should be administered during and after premature rupture of membranes and delivery (Grade 1C)
引用
收藏
页码:487 / 495
页数:9
相关论文
共 32 条
[1]  
[Anonymous], ANT CORT RED NEON MO
[2]  
[Anonymous], RED RISK THROMB EMB
[3]  
[Anonymous], BACT SEPS FOLL PREGN
[4]  
ARTLICH A, 1994, EUR J PEDIATR, V153, P488, DOI 10.1007/BF01957002
[5]  
AVILES A, 1988, MED PEDIATR ONCOL, V16, P3
[6]   ACUTE MYELOGENOUS LEUKEMIA IN PREGNANCY [J].
CANTINI, E ;
YANES, B .
SOUTHERN MEDICAL JOURNAL, 1984, 77 (08) :1050-1052
[7]   Use of chemotherapy during human pregnancy [J].
Cardonick, E ;
Iacobucci, A .
LANCET ONCOLOGY, 2004, 5 (05) :283-291
[8]  
Cheghoum Y., 2005, CANCER, V104, P110
[9]  
Department of Health, 2012, SABTO ADV COMM SAF B
[10]   MANAGEMENT OF CANCER DURING PREGNANCY [J].
DOLL, DC ;
RINGENBERG, QS ;
YARBRO, JW .
ARCHIVES OF INTERNAL MEDICINE, 1988, 148 (09) :2058-2064